Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 3/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | PRNP | P04156 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827081 | 0.83 | CYP1A2 (0.52) | CYP1A2ALDH1A1HSD17B10NCF1NOS2 | |
| Bromide SCHEMBL29161153 | 0.81 | CYP1A2 (0.50) | CYP1A2ALDH1A1HSD17B10NCF1NOS2 | |
| SCHEMBL18426840 | 0.79 | CYP1A2 (0.48) | CYP1A2ALDH1A1HSD17B10NCF1NOS2 | |
| SCHEMBL19133198 | 0.79 | CYP1A2 (0.48) | CYP1A2ALDH1A1HSD17B10NCF1NOS2 | |
| SCHEMBL19557531 | 0.79 | CYP1A2 (0.48) | CYP1A2ALDH1A1HSD17B10NCF1NOS2 | |
| SCHEMBL12915337 | 0.79 | CYP1A2 (0.48) | CYP1A2ALDH1A1HSD17B10NCF1NOS2 | |
| SCHEMBL4064465 | 0.79 | ALDH1A1 (0.50) | CYP1A2ALDH1A1HSD17B10NCF1NOS2 | |
| SCHEMBL20559366 | 0.79 | NCF1 (0.48) | CYP1A2ALDH1A1HSD17B10NCF1NOS2 | |
| SCHEMBL20746476 | 0.79 | NCF1 (0.43) | CYP1A2ALDH1A1HSD17B10NCF1NOS2 | |
| SCHEMBL1261380 | 0.79 | CYP1A2 (0.48) | CYP1A2ALDH1A1HSD17B10NCF1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3556759-B1 | HAPTENS OF PALIPERIDONE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-29 | — | — | EP | disclosed |
| EP-3415516-B1 | HAPTENS OF RISPERIDONE AND PALIPERIDONE | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-15 | — | — | EP | disclosed |
| EP-3305784-B1 | HAPTENS OF QUETIAPINE FOR USE IN IMMUNOASSAYS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-12 | — | — | EP | disclosed |
| CN-107266432-B | Quetiapine haptens for immunoassays | 詹森药业有限公司 | 2020-05-12 | — | — | CN | disclosed |
| EP-3556759-A1 | HAPTENS OF PALIPERIDONE | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| EP-2888258-B1 | HAPTENS OF PALIPERIDONE | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-05 | — | — | EP | disclosed |
| EP-3415516-A1 | HAPTENS OF RISPERIDONE AND PALIPERIDONE | Janssen Pharmaceutica NV (BE) | 2018-12-19 | — | — | EP | disclosed |
| EP-2888263-B1 | HAPTENS OF RISPERIDONE AND PALIPERIDONE | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-09 | — | — | EP | disclosed |
| EP-3305784-A1 | HAPTENS OF QUETIAPINE FOR USE IN IMMUNOASSAYS | Janssen Pharmaceutica NV (BE) | 2018-04-11 | — | — | EP | disclosed |
| EP-2888257-B1 | HAPTENS OF QUETIAPINE FOR USE IN IMMUNOASSAYS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-02 | — | — | EP | disclosed |
| WO-2006047504-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006036883-A2 | IMIDAZO{4,5-B}PYRAZINONE INHIBITORS OF PROTEIN KINASES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| EP-1631560-A2 | C-FMS KINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050131022-A1 | C-fms kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-16 | — | — | US | disclosed |
| US-20050113566-A1 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-26 | — | — | US | disclosed |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
| WO-2005009967-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | WO | disclosed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004096795-A2 | C-FMS KINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131022-A1 | C-fms kinase inhibitors | FLT3, FES, FGR | CYP1A2 3681/4885ALDH1A1 4568/4885HSD17B10 4646/4885 |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | FLT3, ABL1, FES | CYP1A2 1873/4885ALDH1A1 4098/4885HSD17B10 4321/4885 |
| US-20050004112-A1 | C-fms kinase inhibitors | FLT3, FGR, FER | CYP1A2 3555/4885ALDH1A1 4574/4885HSD17B10 4643/4885 |
| US-20050113566-A1 | Inhibitors of C-FMS kinase | ALK, TYRO3, PDGFRB | CYP1A2 1876/4885ALDH1A1 2507/4885HSD17B10 2780/4885 |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | TIE1, KDR, FLT1 | CYP1A2 922/4885ALDH1A1 462/4885HSD17B10 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.